Compare VIRC & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIRC | CRDL |
|---|---|---|
| Founded | 1950 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.0M | 97.3M |
| IPO Year | N/A | N/A |
| Metric | VIRC | CRDL |
|---|---|---|
| Price | $6.51 | $1.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 55.5K | ★ 691.7K |
| Earning Date | 12-08-2025 | 11-13-2025 |
| Dividend Yield | ★ 1.49% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $201,942,000.00 | N/A |
| Revenue This Year | $0.81 | N/A |
| Revenue Next Year | $4.56 | N/A |
| P/E Ratio | $27.71 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.01 | $0.77 |
| 52 Week High | $12.09 | $1.59 |
| Indicator | VIRC | CRDL |
|---|---|---|
| Relative Strength Index (RSI) | 37.88 | 48.25 |
| Support Level | $6.62 | $0.88 |
| Resistance Level | $6.93 | $1.12 |
| Average True Range (ATR) | 0.29 | 0.08 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 37.93 | 58.33 |
Virco Manufacturing Corp is engaged in designing, production and distributing quality furniture for the commercial and education markets. The company manufactures an assortment of products, including mobile tables, mobile storage equipment, desks, computer furniture, chairs, and activity tables, folding chairs, and folding tables. Its primary furniture lines are constructed of tubular metal legs and frames, combined with wood and plastic tops, plastic seats and backs, upholstered seats and backs, and upholstered rigid polyethylene and polypropylene shells.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.